These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 1769944

  • 1. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
    Cherubin CE, Eng RH, Smith SM, Tan EN.
    J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S, Marre R.
    Infection; 1991 Feb; 19(2):106-9. PubMed ID: 1646771
    [Abstract] [Full Text] [Related]

  • 5. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM, Seetulsingh P.
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [Abstract] [Full Text] [Related]

  • 6. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
    Vanjak D, Muller-Serieys C, Picard B, Bergogne-Berezin E, Lambert-Zechovsky N.
    Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
    [Abstract] [Full Text] [Related]

  • 7. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S, Hanaki H, Nagayama A.
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA, Rudin SA, Shlaes DM.
    FEMS Microbiol Lett; 1997 Mar 01; 148(1):59-62. PubMed ID: 9066111
    [Abstract] [Full Text] [Related]

  • 11. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
    Lachance N, Gaudreau C, Lamothe F, Turgeon F.
    Antimicrob Agents Chemother; 1993 May 01; 37(5):1174-6. PubMed ID: 8390812
    [Abstract] [Full Text] [Related]

  • 12. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J.
    Antimicrob Agents Chemother; 2013 May 01; 57(5):2109-13. PubMed ID: 23439636
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
    Martín MA, Castillo AM, Liébana J, Marín A, Alados JC, Piédrola G.
    J Hyg Epidemiol Microbiol Immunol; 1991 May 01; 35(2):189-97. PubMed ID: 1940333
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
    Sirot D, Chanal C, Henquell C, Labia R, Sirot J, Cluzel R.
    J Antimicrob Chemother; 1994 Jun 01; 33(6):1117-26. PubMed ID: 7928805
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.